Table 1.
The baseline characteristics of patients
| Characteristics | n (%) |
|---|---|
| Age | |
| Average | 43 years |
| Range | 15–78 years |
| Gender | |
| Male | 14 (58) |
| Female | 10 (42) |
| ECOG performance status | |
| 0 | 3 (12.5) |
| 1 | 15 (62.5) |
| 2 | 5 (20.8) |
| 3 | 1 (4.2) |
| Tumor type | |
| Soft tissue sarcoma | 17 (70.8) |
| Synovial sarcoma | 3 |
| Liposarcoma | 4 |
| UPS | 3 |
| Rhabdomyosarcoma | 2 |
| Leiomyosarcoma | 2 |
| Clear cell sarcoma | 2 |
| MPNST | 1 |
| Non-soft tissue sarcoma | 7 (29.2) |
| Osteosarcoma | 5 |
| Chondrosarcoma | 2 |
| Primary location | |
| Extremity | 12 (50.0) |
| Abdominal/pelvis | 2 (8.3) |
| Chest | 2 (8.3) |
| Axial | 8 (33.4) |
| Treatment strategy | |
| Mono pembrolizumab | 3 |
| Camrilizumab combined with apatinib | 20 |
| Pembrolizumab combined with radiotherapy | 1 |
ECOG, Eastern Cooperative Oncology Group; UPS, undifferentiated pleomorphic sarcoma; MPNST, malignant peripheral nerve sheath tumor.